Cannabis for ALS

ALS is a devastating neurodegenerative disease with limited treatment options. Cannabis shows neuroprotective, antioxidant, and anti-excitotoxic properties that directly address multiple ALS disease mechanisms — and is one of the few evidence-backed options for ALS symptom management.

30,000 (US)
ALS Patients
73%
Spasm Relief
Neuroprotection
Key Property
Cannabis for ALS

Neuroprotective Properties for ALS

ALS involves progressive motor neuron death driven by excitotoxicity, oxidative stress, and neuroinflammation — all targets of cannabinoids. CBD is a potent antioxidant (equivalent to vitamins C and E in reducing oxidative stress). THC and CBD reduce glutamate-mediated excitotoxicity — the primary driver of motor neuron death in ALS. Animal studies show cannabis delays ALS onset and progression. While human disease-modification data is limited, the mechanism aligns precisely with ALS pathology.

Symptom Management in ALS

ALS causes muscle spasticity, pain, secretion management problems, and depression. Cannabis addresses all four. Spasticity responds to THC+CBD combination. Drooling (sialorrhea) — a common ALS complaint — is reduced by cannabis (anticholinergic-like effect). Cannabis also improves respiratory muscle function in some patients, which may have survival implications. THC anti-emetic effects help patients on feeding tubes tolerate tube-feeding formulas.

ALS and Medical Cannabis Access

ALS qualifies for medical cannabis in most US states due to its terminal nature. Many states have expedited application processes for terminal illnesses. The ALS Association formally endorsed patient access to cannabis in 2019. Because ALS can affect swallowing and breathing, delivery method choice is critical: sublingual tinctures are preferred over smoking for patients with respiratory involvement. Suppositories and transdermal patches are options for advanced ALS patients with significant swallowing difficulties.

Working with ALS Care Teams

ALS multidisciplinary care teams increasingly include cannabis medicine consultation. Major ALS centers at Johns Hopkins, Massachusetts General, and Mayo Clinic have clinical cannabis protocols. Cannabis does not negatively interact with riluzole (the primary ALS medication) or edaravone at therapeutic doses. Caregivers play a crucial role in cannabis administration for ALS patients — tincture drop administration and patch application are manageable tasks that provide significant symptom relief in a condition with few effective options.

Trusted Sources

Frequently Asked Questions

Cannabis is not FDA-approved to treat ALS. However, ALS qualifies for medical cannabis in most US states, and the ALS Association officially supports patient access to cannabis for symptom management.
Animal studies suggest cannabinoids may slow motor neuron death. Human disease-modification evidence is limited to retrospective studies. Cannabis is primarily used for symptom management, though neuroprotective benefits may occur.
Spasticity, pain, drooling (sialorrhea), sleep problems, and depression are the ALS symptoms most reliably helped by cannabis. These significantly impact quality of life in ALS.
Sublingual tinctures are preferred for most ALS patients. For those with swallowing difficulties, transdermal patches or suppositories provide alternatives. Smoking is not recommended for patients with respiratory involvement.
No significant pharmacokinetic interactions between cannabis and riluzole have been documented. Cannabis appears safe to combine with the standard ALS medication at therapeutic doses.

Related Guides